Dabur India gets SEBI warning for delayed disclosure of US FDA letter
- Legal
- Personal Care
Reviewed byKeshav SehgalBlacklitt Research
Dabur India (NSE: DABUR) has received an administrative warning and advice letter from the Securities and Exchange Board of India over a delay in disclosing a US FDA warning letter, it said in a filing on 06 Nov 2026. SEBI warned the company and its board to be careful in future and said repetition would be viewed seriously.
What SEBI alleges and warns
SEBI alleges that Dabur India violated Regulation 30(6)(iii) of the SEBI Listing Regulations through a delay in making disclosure. The delayed item was a warning letter the company received from the US FDA on July 24, 2026.
The letter warns the company and its Board of Directors to be careful in future to avoid recurrence of such lapses. It says any repetition will be viewed seriously and that appropriate enforcement action would follow under the SEBI Act, 1992, its rules, regulations and circulars.
SEBI also advised the company to place the letter before its board at the upcoming board meeting and to forward the board's comments to SEBI on whether it is satisfied with the corrective steps taken.
The company's response
The company says there is no impact on its financial operations and other activities from the warning letter. It also says it has always been the most compliant in following the SEBI Listing Regulations.
The company says it will take necessary steps to address the concern or directive in the SEBI letter. The filing does not describe those steps or set a timeline for them.
What the SEBI warning means for Dabur India's shareholders
The letter is an administrative warning, not a penalty, and the company states no financial or operational impact. The company's latest quarter, Q2 FY27, reported consolidated net profit of ₹498.57 crore, up 12.1% year on year, but the filing does not link the warning to those results.
Not stated: the corrective steps the company has taken or will take, their timeline, whether the US FDA letter has since been disclosed to the exchanges, and whether the board has yet considered the SEBI letter. The next step is the board meeting at which the letter is to be placed before directors.
At a glance
| Item | Detail |
|---|---|
| Authority | Securities and Exchange Board of India |
| Action | Administrative warning and advice letter |
| Letter received | 06 Nov 2026 at 12.40 p.m., by email |
| Delayed disclosure | US FDA warning letter received 24 Jul 2026 |
Filed with NSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.